Phase II study of preoperative radiotherapy with capecitabine and oxaliplatin for rectal cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIC-17011632

Enrollment

Unknown

Registered

2017-06-11

Start date

2007-03-19

Completion date

Unknown

Last updated

2017-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer

Interventions

Case series:pre-operative radiotherapy with concurrent capecitabine and oxaliplatin

Eligibility

Sex/Gender

Male

Age

26 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients were sequentially enrolled between March 2007 and June 2008 if they accorded with the following criteria: age between 18 and 75 years; previously untreated rectal cancer; histologically proven rectal adenocarcinomas; TMN stage of T3-T4 or positive regional lymph nodes confirmed by CT, and/or magnetic resonance images(MRI), endorectal ultrasonography(ERUS); tumor location within 10cm above anal verge; Eastern Cooperative Oncology Group(ECOG) performance status scores=2.

Exclusion criteria

Exclusion criteria: The exclusion criteria were as follow: (1) metastatic disease before or during preoperative treatment; and (2) other active malignancy (except for basal cell carcinoma of the skin).

Design outcomes

Primary

Measure	Time frame
pCR;	—

Secondary

Measure	Time frame
DFS;OS;Post surgery complications;Toxicity of chemotherapy;	—

Contacts

Public ContactZhizhong Pan

Sun Yat-sen University Cancer Center

panzhzh@sysucc.org.cn+86 13719388166

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026